for the Period Ended 31 October 2023
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
As at
Notes | 2023 | 2022 | |
---|---|---|---|
| £ | £ | |
Fixed assets | |||
Intangible assets: | 3 | | |
Total fixed assets: | | | |
Current assets | |||
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 4 | ( | ( |
Net current assets (liabilities): | ( | ( | |
Total assets less current liabilities: | ( | ( | |
Total net assets (liabilities): | ( | ( | |
Members' funds | |||
Profit and loss account: | ( | ( | |
Total members' funds: | ( | ( |
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 October 2023
Basis of measurement and preparation
for the Period Ended 31 October 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 October 2023
Goodwill | Other | Total | |
---|---|---|---|
Cost | £ | £ | £ |
At 1 November 2022 | | | |
Additions | |||
Disposals | |||
Revaluations | |||
Transfers | |||
At 31 October 2023 | | | |
Amortisation | |||
At 1 November 2022 | | | |
Charge for year | | | |
On disposals | |||
Other adjustments | |||
At 31 October 2023 | | | |
Net book value | |||
At 31 October 2023 | | | |
At 31 October 2022 | | |
for the Period Ended 31 October 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Other creditors | | |
Total | | |
The company has continued to develop self-refraction glasses for use in the developing world, where there are too few eye care professionals to serve the population. During the period the company has continued to work with its manufacturing partner to bring the glasses into production and to develop distribution programmes in conjunction with NGOs and other potential distributors in the developing world. The company has also continued to work with research partners in relation to clinical trials of the new glasses.
The company's stakeholders are our distribution partners comprising NGOs and school programmes in the developing world; clinical researchers in the field of self-refraction and refractive vision correction; and end-users in the developing world who need but do not currently have access to vision correction. The company has consulted with potential distribution partners in order to design pilot distribution programmes. The company has also consulted with clinical researchers in relation to clinical trials of the new glasses.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
31 July 2024
And signed on behalf of the board by:
Name: Christopher Wray
Status: Director